The Return of Gene Therapy

Gene therapy is a hot area in the biotech industry right now, with many treatments in development and a number of recent approvals. However, the path has not always been a smooth one.

Gene therapy has been one of the biggest success stories of the 21st century. Genetic diseases were once seen as incurable, etched in stone (or rather, in nucleotides) within the genomes of those unfortunate enough to receive them in life’s genetic lottery. Not anymore.

Over the last few years, there has been a near constant stream of positive news around gene therapy, with treatment after treatment receiving regulatory approval, succeeding in trials, or raising vast sums to enter development. And with over 1,000 clinical trials currently underway, we may finally be witnessing the long-awaited arrival of the gene therapy revolution.

The field has had a long and often bumpy road to get to this point, with both triumph and tragedy along the way. Let’s take a look back at gene therapy’s evolution from futuristic idea to tangible treatment, and what is still to come.

The early years

In 1972, a paper titled ‘Gene therapy for human genetic disease?’ was published in Science by US scientists Theodore Friedmann and Richard Roblin, who outlined the immense potential of incorporating DNA sequences into patients’ cells for treating people with genetic disorders.

The post The Return of Gene Therapy appeared first on Labiotech.eu.

Published on Wed, 04 Nov 2020 11:50:50 +0000 on behalf of nintex convert array to xml